Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,426JPY
2:29am GMT
Change (% chg)

¥-23 (-0.52%)
Prev Close
¥4,449
Open
¥4,400
Day's High
¥4,463
Day's Low
¥4,383
Volume
5,133,100
Avg. Vol
9,683,529
52-wk High
¥6,659
52-wk Low
¥3,498

Latest Key Developments (Source: Significant Developments)

Takeda's Global Acquisition Of Shire Creates An Expanded Takeda Canada
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA'S GLOBAL ACQUISITION OF SHIRE CREATES AN EXPANDED TAKEDA CANADA TO BRING BETTER HEALTH AND A BRIGHTER FUTURE TO CANADIANS.  Full Article

Shire Says Following Court Order, Scheme Has Now Become Effective
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Shire Plc::SHIRE PLC - FOLLOWING COURT ORDER , SCHEME HAS NOW BECOME EFFECTIVE, ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Takeda - Notice Regarding Amounts Of Capital And Capital Reserves To Be Increased By Issuance Of New Shares In Connection With Shire Acquisition
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING AMOUNTS OF CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ISSUANCE OF NEW SHARES IN CONNECTION WITH SHIRE ACQUISITION.AMOUNTS OF BOTH STATED CAPITAL AND CAPITAL RESERVES TO BE INCREASED BY ABOUT 1.565 TRLN YEN EACH.  Full Article

Takeda Says It Now Owns Entire Issued And To Be Issued Share Capital Of Shire
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::NOTICE REGARDING THE ACQUISITION OF THE ENTIRE ISSUED AND TO BE ISSUED SHARE OF SHIRE.CONFIRMS SCHEME OF ARRANGEMENT IN RELATION TO PROPOSED ACQUISITION OF SHIRE BECAME EFFECTIVE JAN 8.ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF SHIRE IS NOW OWNED BY TAKEDA.  Full Article

Shire Plc Says Thomas Dittrich, Chief Financial Officer And Executive Director, Has Resigned
Tuesday, 8 Jan 2019 

Jan 7 (Reuters) - Shire Plc ::SAYS THOMAS DITTRICH, CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR, HAS RESIGNED.ANNOUNCES THAT DIRECTORS OF SHIRE HAVE TENDERED THEIR RESIGNATIONS.SHIRE-FLEMMING ORNSKOV WILL BE RETAINED BY SHIRE AS EMPLOYEE TO ACT IN AN ADVISORY CAPACITY TO CEO OF TAKEDA FOR THREE MONTHS ENDING ON MARCH 31, 2019.FLEMMING ORNSKOV, CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR, HAS RESIGNED.SHIRE - THOMAS DITTRICH WILL BE RETAINED BY SHIRE AS AN EMPLOYEE TO ACT IN ADVISORY CAPACITY TO CHIEF FINANCIAL OFFICER OF TAKEDA UNTIL MARCH 3, 2019.TAKEDA HAS APPOINTED OLIVIER BOHUON, IAN CLARK AND STEVEN GILLIS TO THE TAKEDA BOARD EFFECTIVE AS OF TODAY’S DATE.AMONG DIRECTORS OF SHIRE TO HAVE TENDERED RESIGNATION IS SUSAN KILSBY, NON-EXECUTIVE DIRECTOR AND CHAIRMAN.  Full Article

Takeda CEO Says Selling Consumer Business Is Not Our First Priority In Terms Of Accelerating Deleverage
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Takeda <4502.T>::CEO SAYS SELLING CONSUMER BUSINESS IS NOT OUR FIRST PRIORITY IN TERMS OF ACCELERATING DELEVERAGE.  Full Article

Takeda Announces Listing Of American Depositary Shares On The New York Stock Exchange
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ANNOUNCES LISTING OF AMERICAN DEPOSITARY SHARES ON THE NEW YORK STOCK EXCHANGE.TAKEDA PHARMACEUTICAL CO LTD - LISTING AND TRADING OF ADSS ON NYSE EXPECTED TO COMMENCE ON DECEMBER 24, 2018.TAKEDA PHARMACEUTICAL CO LTD - ADSS WILL NOW TRADE UNDER TICKER SYMBOL "TAK".TAKEDA PHARMACEUTICAL - TO MAINTAIN HEADQUARTERS IN JAPAN AND PRIMARY LISTING ON TSE AS WELL AS CURRENT LISTINGS ON LOCAL JAPANESE STOCK EXCHANGES.  Full Article

Takeda Receives Positive CHMP Opinion For Adcetris For Treating Adults With A Certain Stage Of Hodgkin Lymphoma
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CD30+ STAGE IV HODGKIN LYMPHOMA IN COMBINATION WITH AVD.TAKEDA PHARMACEUTICAL CO LTD - SUBMISSION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC).TAKEDA PHARMACEUTICAL CO LTD - CHMP OPINION FOR ADCETRIS (BRENTUXIMAB VEDOTIN) BASED ON POSITIVE PHASE 3 ECHELON-1 STUDY RESULTS.  Full Article

Takeda CFO says plans up to $10 bln in asset sales after Shire -Nikkei
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL CFO SAYS PLANS UP TO $10 BILLION IN ASSET SALES AFTER SHIRE ACQUISITION TO REDUCE INTEREST-BEARING DEBT - NIKKEI.  Full Article

Takeda Pharmaceutical to issue unsecured U.S. dollar denominated senior notes worth $5.5 bln
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it will issue unsecured U.S. dollar denominated senior notes worth $5.5 billion .The Notes will be issued in order to finance a portion of the funds necessary for the acquisition of Shire plc and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 .  Full Article

Nikkei dips as global growth concerns sap risk appetite

TOKYO, Jan 22 Japan's Nikkei edged lower on Tuesday in choppy trade, retreating from a one-month high as investors took profits from recent gainers amid concerns about slowing global economic growth.